PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma

Motofumi Kumazoe, Mika Takai, Shun Hiroi, Chieri Takeuchi, Maasa Yamanouchi, Takashi Nojiri, Hiroaki Onda, Jaehoon Bae, Yuhui Huang, Kanako Takamatsu, Shuya Yamashita, Shuhei Yamada, Kenji Kangawa, Takashi Takahashi, Hiroshi Tanaka, Hirofumi Tachibana

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recurrence following chemotherapy is observed in the majority of patients with pancreatic ductal adenocarcinoma (PDAC). Recent studies suggest that cancer stem cells (CSCs) may be involved in PDAC recurrence and metastasis. However, an efficient approach to targeting pancreatic CSCs remains to be established. Here we show that in cancer cells overexpressing the 67-kDa laminin receptor (67LR)-dependent cyclic GMP (cGMP) inducer, epigallocatechin-3-O-gallate (EGCG) and a phosphodiesterase 3 (PDE3) inhibitor in combination significantly suppressed the Forkhead box O3 and CD44 axis, which is indispensable for the CSC properties of PDAC. We confirmed that the EGCG and PDE3 inhibitor in combination strongly suppressed tumour formation and liver metastasis in vivo. We also found that a synthesized EGCG analog capable of inducing strong cGMP production drastically suppressed the CSC properties of PDAC and extended the survival period in vivo. In conclusion, the combination treatment of EGCG and a PDE3 inhibitor as a strong cGMP inducer could be a potential treatment candidate for the eradication of CSCs of PDAC.

Original languageEnglish
Article number1917
JournalScientific reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Phosphodiesterase 3 Inhibitors
Neoplastic Stem Cells
Adenocarcinoma
Cyclic GMP
Laminin Receptors
Neoplasm Metastasis
Therapeutics
Recurrence
Pancreatic Neoplasms
Neoplasms
epigallocatechin gallate
Drug Therapy
Survival
Liver

All Science Journal Classification (ASJC) codes

  • General

Cite this

PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. / Kumazoe, Motofumi; Takai, Mika; Hiroi, Shun; Takeuchi, Chieri; Yamanouchi, Maasa; Nojiri, Takashi; Onda, Hiroaki; Bae, Jaehoon; Huang, Yuhui; Takamatsu, Kanako; Yamashita, Shuya; Yamada, Shuhei; Kangawa, Kenji; Takahashi, Takashi; Tanaka, Hiroshi; Tachibana, Hirofumi.

In: Scientific reports, Vol. 7, No. 1, 1917, 01.12.2017.

Research output: Contribution to journalArticle

Kumazoe, M, Takai, M, Hiroi, S, Takeuchi, C, Yamanouchi, M, Nojiri, T, Onda, H, Bae, J, Huang, Y, Takamatsu, K, Yamashita, S, Yamada, S, Kangawa, K, Takahashi, T, Tanaka, H & Tachibana, H 2017, 'PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma', Scientific reports, vol. 7, no. 1, 1917. https://doi.org/10.1038/s41598-017-02162-9
Kumazoe, Motofumi ; Takai, Mika ; Hiroi, Shun ; Takeuchi, Chieri ; Yamanouchi, Maasa ; Nojiri, Takashi ; Onda, Hiroaki ; Bae, Jaehoon ; Huang, Yuhui ; Takamatsu, Kanako ; Yamashita, Shuya ; Yamada, Shuhei ; Kangawa, Kenji ; Takahashi, Takashi ; Tanaka, Hiroshi ; Tachibana, Hirofumi. / PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. In: Scientific reports. 2017 ; Vol. 7, No. 1.
@article{7182bb11159f42cc80fac975a33b32b7,
title = "PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma",
abstract = "Recurrence following chemotherapy is observed in the majority of patients with pancreatic ductal adenocarcinoma (PDAC). Recent studies suggest that cancer stem cells (CSCs) may be involved in PDAC recurrence and metastasis. However, an efficient approach to targeting pancreatic CSCs remains to be established. Here we show that in cancer cells overexpressing the 67-kDa laminin receptor (67LR)-dependent cyclic GMP (cGMP) inducer, epigallocatechin-3-O-gallate (EGCG) and a phosphodiesterase 3 (PDE3) inhibitor in combination significantly suppressed the Forkhead box O3 and CD44 axis, which is indispensable for the CSC properties of PDAC. We confirmed that the EGCG and PDE3 inhibitor in combination strongly suppressed tumour formation and liver metastasis in vivo. We also found that a synthesized EGCG analog capable of inducing strong cGMP production drastically suppressed the CSC properties of PDAC and extended the survival period in vivo. In conclusion, the combination treatment of EGCG and a PDE3 inhibitor as a strong cGMP inducer could be a potential treatment candidate for the eradication of CSCs of PDAC.",
author = "Motofumi Kumazoe and Mika Takai and Shun Hiroi and Chieri Takeuchi and Maasa Yamanouchi and Takashi Nojiri and Hiroaki Onda and Jaehoon Bae and Yuhui Huang and Kanako Takamatsu and Shuya Yamashita and Shuhei Yamada and Kenji Kangawa and Takashi Takahashi and Hiroshi Tanaka and Hirofumi Tachibana",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02162-9",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma

AU - Kumazoe, Motofumi

AU - Takai, Mika

AU - Hiroi, Shun

AU - Takeuchi, Chieri

AU - Yamanouchi, Maasa

AU - Nojiri, Takashi

AU - Onda, Hiroaki

AU - Bae, Jaehoon

AU - Huang, Yuhui

AU - Takamatsu, Kanako

AU - Yamashita, Shuya

AU - Yamada, Shuhei

AU - Kangawa, Kenji

AU - Takahashi, Takashi

AU - Tanaka, Hiroshi

AU - Tachibana, Hirofumi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Recurrence following chemotherapy is observed in the majority of patients with pancreatic ductal adenocarcinoma (PDAC). Recent studies suggest that cancer stem cells (CSCs) may be involved in PDAC recurrence and metastasis. However, an efficient approach to targeting pancreatic CSCs remains to be established. Here we show that in cancer cells overexpressing the 67-kDa laminin receptor (67LR)-dependent cyclic GMP (cGMP) inducer, epigallocatechin-3-O-gallate (EGCG) and a phosphodiesterase 3 (PDE3) inhibitor in combination significantly suppressed the Forkhead box O3 and CD44 axis, which is indispensable for the CSC properties of PDAC. We confirmed that the EGCG and PDE3 inhibitor in combination strongly suppressed tumour formation and liver metastasis in vivo. We also found that a synthesized EGCG analog capable of inducing strong cGMP production drastically suppressed the CSC properties of PDAC and extended the survival period in vivo. In conclusion, the combination treatment of EGCG and a PDE3 inhibitor as a strong cGMP inducer could be a potential treatment candidate for the eradication of CSCs of PDAC.

AB - Recurrence following chemotherapy is observed in the majority of patients with pancreatic ductal adenocarcinoma (PDAC). Recent studies suggest that cancer stem cells (CSCs) may be involved in PDAC recurrence and metastasis. However, an efficient approach to targeting pancreatic CSCs remains to be established. Here we show that in cancer cells overexpressing the 67-kDa laminin receptor (67LR)-dependent cyclic GMP (cGMP) inducer, epigallocatechin-3-O-gallate (EGCG) and a phosphodiesterase 3 (PDE3) inhibitor in combination significantly suppressed the Forkhead box O3 and CD44 axis, which is indispensable for the CSC properties of PDAC. We confirmed that the EGCG and PDE3 inhibitor in combination strongly suppressed tumour formation and liver metastasis in vivo. We also found that a synthesized EGCG analog capable of inducing strong cGMP production drastically suppressed the CSC properties of PDAC and extended the survival period in vivo. In conclusion, the combination treatment of EGCG and a PDE3 inhibitor as a strong cGMP inducer could be a potential treatment candidate for the eradication of CSCs of PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85019434595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019434595&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02162-9

DO - 10.1038/s41598-017-02162-9

M3 - Article

C2 - 28507327

AN - SCOPUS:85019434595

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1917

ER -